11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 27.04.2026 Expectation: 7500 pips
Selling silver with $72.5 in sight
Today at 11:08 AM 29
Period: 27.04.2026 Expectation: 1300 pips
S&P 500 Index shows signs of fading bullish momentum amid geopolitical fog
Today at 10:05 AM 18
Gold sell
Period: 30.04.2026 Expectation: 3800 pips
Gold sell-off targets $4,750
Today at 08:25 AM 27
Period: 30.04.2026 Expectation: 300 pips
Selling EURUSD down to 1.17720
Today at 08:25 AM 11
Gold sell
Period: 04.05.2026 Expectation: 190 pips
Gold feels heat from Middle East headlines
Today at 08:06 AM 25
Period: 27.04.2026 Expectation: 830 pips
EURUSD remains resilient to escalating Middle East situation
Today at 06:53 AM 20
Go to forecasts